XOMA
XOMA Corp

7,346
Mkt Cap
$368.52M
Volume
96,234.00
52W High
$39.92
52W Low
$18.35
PE Ratio
41.58
XOMA Fundamentals
Price
$31.00
Prev Close
$29.76
Open
$29.94
50D MA
$34.54
Beta
0.79
Avg. Volume
54,593.53
EPS (Annual)
-$1.65
P/B
4.34
Rev/Employee
$2.19M
Loading...
Loading...
News
all
press releases
XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200-Day Moving Average - What's Next...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
XOMA Royalty (NASDAQ:XOMA) Lowered to Strong Sell Rating by Zacks Research
Zacks Research lowered XOMA Royalty from a "hold" rating to a "strong sell" rating in a report on Tuesday...
MarketBeat·13d ago
News Placeholder
Los Angeles Capital Management LLC Invests $370,000 in XOMA Royalty Corporation $XOMA
Los Angeles Capital Management LLC purchased a new stake in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) in the second quarter, according to its most recent disclosure with the Securities...
MarketBeat·17d ago
News Placeholder
Leerink Partnrs Expects Stronger Earnings for XOMA Royalty
XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2029 earnings estimates for XOMA Royalty in a report released on Wednesday...
MarketBeat·19d ago
News Placeholder
XOMA Royalty (NASDAQ:XOMA) Issues Quarterly Earnings Results, Misses Expectations By $0.33 EPS
XOMA Royalty (NASDAQ:XOMA - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates...
MarketBeat·19d ago
News Placeholder
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of -1,650.00% and -25.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.00% and -21.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22d ago
News Placeholder
Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of +1,200.00% and +23.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·30d ago
News Placeholder
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -30.30% and +8.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.
Zacks·1mo ago

Latest XOMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.